Dr Scott M. Rocklage is an exceptionally qualified medical physician who has been in the industry for more than two decades and has led to the FDA approval of 3 U.S New Drug Applications; i.e. Comniscan™, Teslascan®, and Cubicin®. He has also entered six drug candidates into clinical trials.
He joined 5 AM Ventures LLC in 2003 as a venturing partner and became a managing partner in 2004. He defines the firm as a life science-based venture capital firm. It aids the science community in further developing projects that will help human life to survive longer on earth.
Scott Rocklage attained his B.S in chemistry from the University of California, Berkeley, and went further ahead to pursue his PhD from the Massachusetts Institute of Technology where he researched in Richard R. Schrock’s lab, the Nobel Prize winner in Chemistry in 2005. He is currently based in Boston, MA office.
Despite his managing partner role, Scott Rocklage has had numerous titles throughout the years. He was the Chief Executive Officer and Chairman of Cubist Pharmaceuticals, President and Chief Executive Officer at Nycomed Salutar and Nycomed Interventional and similarly, has served in various R&D positions at Salutar and Catlytica.
He has also had positions as Board Chairman of Relypsa, Achaogen, and Novira. He has been a Board member in EPIRUS and Pulmatrix as well. He was the former executive chairman of Ilypsa, Miikana Therapeutics Inc, and Semprus BioSciences Corp. He currently is the Board chairman of Rennovia Inc., Kinestral, and Cidara Therapeutics Inc.
To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.